PF 5221304

Drug Profile

PF 5221304

Alternative Names: PF05221304

Latest Information Update: 17 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-alcoholic steatohepatitis

Most Recent Events

  • 17 Aug 2017 Pfizer plans a phase II trial for Non-alcoholic steatohepatitis (NCT03248882)
  • 27 Mar 2017 Pfizer completes a phase I trial in Non-alcoholic steatohepatitis (In volunteers) in USA (PO) (NCT02871037)
  • 01 Aug 2016 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in USA (PO) (NCT02871037 and Pfizer pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top